BA
Therapeutic Areas
Ocular Therapeutix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DEXTENZA | Post-surgical ocular inflammation & pain | Approved |
| OTX-TKI (axitinib implant) | Wet Age-Related Macular Degeneration (wet AMD) | Phase 3 |
| OTX-CSI (cyclosporine insert) | Dry Eye Disease | Phase 3 |
| OTX-DED (dexamethasone insert) | Episodic Dry Eye Disease Flares | Phase 2 |
| OTX-TIC (travoprost insert) | Glaucoma / Ocular Hypertension | Phase 1 |
Leadership Team at Ocular Therapeutix
AM
Antony Mattessich
President and Chief Executive Officer
DN
Donald Notman
Chief Financial Officer
MG
Michael Goldstein
Chief Medical Officer
J(
John (Jay) D. Peter
Chief Development Officer
RG
Rabia Gurses Ozden
Chief Strategy Officer
SC
Scott Corring
Senior Vice President, Commercial
AR
Andrew R. Calin
Independent Director
LJ
Leslie J. Williams
Independent Director
MR
Merilee Raines
Independent Director
JF
Joseph F. Damico
Independent Director